Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Pharmacokinetic Study of an Experimental Paracetamol Formulation

Phase 1

Completed

Conditions: Headache, Tension-Type

Interventions: Drug: Paracetamol marketed formulation
Drug: Experimental paracetamol

First Posted Date: 2011-11-22

Last Posted Date: 2014-11-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT01476176

Locations: 🇺🇸
MDS Pharma Services ARIZONA, Phoenix, Arizona, United States

A Pharmacokinetic Study Investigating the Rate and Extent of Paracetamol Absorption of Three Experimental Sustained Release Pediatric Suspensions

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Paracetamol fast dissolution suspension
Drug: Paracetamol medium dissolution suspension
Drug: Paracetamol slow dissolution suspension
Drug: Paracetamol

First Posted Date: 2011-11-22

Last Posted Date: 2014-11-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 18

Registration Number: NCT01476215

Locations: 🇺🇸
MDS Pharma Services NEBRASKA, Lincoln, Nebraska, United States

A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Experimental paracetamol formulation
Drug: Marketed paracetamol
Drug: Higher dose marketed paracetamol

First Posted Date: 2011-11-22

Last Posted Date: 2014-11-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 28

Registration Number: NCT01476189

Locations: 🇺🇸
MDS Pharma Services NEBRASKA, Lincoln, Nebraska, United States

Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer

Terminated

Conditions: Neoplasms, Breast

First Posted Date: 2011-11-22

Last Posted Date: 2015-03-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 117

Registration Number: NCT01476111

Locations: 🇬🇧
GSK Investigational Site, Poole, United Kingdom

Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose - ADERE PROJECT

Phase 4

Completed

Conditions: Asthma

Interventions: Other: Telephone follow-up
Other: No telephone follow-up

First Posted Date: 2011-11-22

Last Posted Date: 2017-06-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 472

Registration Number: NCT01476059

A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: GSK1120212
Drug: GSK2110183

First Posted Date: 2011-11-22

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 335

Registration Number: NCT01476137

Locations: 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States

GSK2251052 Mass Balance in Healthy Adult Subjects

Phase 1

Completed

Conditions: Community-acquired Infection

Interventions: Drug: 14C GSK2251052

First Posted Date: 2011-11-21

Last Posted Date: 2017-06-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 6

Registration Number: NCT01475695

Locations: 🇳🇱
GSK Investigational Site, Zuidlaren, Netherlands

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: ADVAIR 100/50mcg
Drug: ADVAIR 250/50mcg
Drug: ADVAIR 500/50mcg
Drug: FLOVENT 500mcg
Drug: FLOVENT 100mcg
Drug: FLOVENT 250mcg

First Posted Date: 2011-11-21

Last Posted Date: 2018-08-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 11751

Registration Number: NCT01475721

Locations: 🇬🇧
GSK Investigational Site, Stoke on Trent, United Kingdom

Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Biological: placebo
Biological: albiglutide

First Posted Date: 2011-11-21

Last Posted Date: 2017-01-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 44

Registration Number: NCT01475734

Locations: 🇺🇸
GSK Investigational Site, Chula Vista, California, United States

Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs

Phase 3

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: GSK548470 300 mg tablet

First Posted Date: 2011-11-21

Last Posted Date: 2015-06-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 34

Registration Number: NCT01475851

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy